Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Completed · Phase 1

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

Key facts

Study ID

NCT00005633

Run by

Memorial Sloan Kettering Cancer Center

Starts

1999-06-01

Expected to finish

2002-06-01

Last updated by the study team

2013-06-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.